Marie-Claire Letellier

Bone Therapeutics — Belgium

Neuroscience · Life Sciences

5h-index198citations21works6.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tryptophan and brain disorders(15), Treatment of Major Depression(5), Gut microbiota and health(3), Immune cells in cancer(3), Pharmacological Receptor Mechanisms and Effects(3)

Publications20 total

ENT1 inhibition enhances weight control and metabolic health in diet-induced obesity
Biomedicine & Pharmacotherapy·2025Open Access
Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer
Nature Immunology·2025· 19 citedOpen Access
Abstract 5609: A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response
Cancer Research·2025
Data from Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
2023Open Access
Supplementary Table 1 and Supplementary Figures 1-5 from Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
2023Open Access
Data from Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
2023Open Access
Supplementary Table 1 and Supplementary Figures 1-5 from Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
2023Open Access
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
Cancer Immunology Research·2019· 54 citedOpen Access
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Molecular Cancer Therapeutics·2018· 83 citedOpen Access
Abstract 4612: Development and validation of a screening platform for the identification of novel immuno-oncology targets
Cancer Research·2017
Abstract B030: Development and validation of a phenotypic screening platform for the identification of novel immuno-oncology targets
Cancer Immunology Research·2016
Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors
Cancer Research·2016· 25 cited

Frequent Co-authors

Benoı̂t J. Van den Eynde(14), Reece Marillier(13), Sandra Cauwenberghs(12), Stefano Crosignani(12), Virginie Rabolli(12), Grégory Driessens(10), Deepak Dalvie(10), Sofie Denies(10), Karen A. Maegley(10), Nichol Miller(10), Romain Pirson(10), Chad Ray(10), Nicole Streiner(10), Vince R. Torti(10), Konstantinos Tsaparikos(10), Martin Wythes(10), Joseph R. Tumang(10), Derek W. Bartlett(9), Danying Cai(9), Christopher P. Dillon(9)